Reply to Zhu et al.: Implications of CHRNB1 and ERBB2 in the pathobiology of myasthenia gravis

Proc Natl Acad Sci U S A. 2022 Sep 9;119(36):e2209096119. doi: 10.1073/pnas.2209096119. Epub 2022 Aug 15.

Authors

Ruth Chia¹, Sara Saez-Atienzar¹, Daniel B Drachman², Bryan J Traynor^{1

2

3

4}

Affiliations

¹ Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892.
² Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21287.
³ Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London WC1N 1PJ, United Kingdom.
⁴ National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Intramural
Comment

MeSH terms

Humans
Myasthenia Gravis* / genetics
Myasthenia Gravis* / pathology
Receptor, ErbB-2* / genetics
Receptors, Nicotinic* / genetics
Thymectomy

Substances

CHRNB1 protein, human
Receptors, Nicotinic
ERBB2 protein, human
Receptor, ErbB-2

Grants and funding

Z01 AG000949/ImNIH/Intramural NIH HHS/United States